Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTA NASDAQ:IMVT NASDAQ:SRRK NASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTACentessa Pharmaceuticals$39.60+0.1%$34.74$10.95▼$40.26$5.91B1.132.28 million shs1.62 million shsIMVTImmunovant$28.96-1.0%$26.25$13.63▼$30.16$5.89B0.71.44 million shs1.22 million shsSRRKScholar Rock$51.28+2.2%$46.48$27.07▼$51.63$6.14B0.71.34 million shs2.21 million shsURGNUrogen Pharma$29.68-4.1%$21.37$3.42▼$32.37$1.45B1.58826,948 shs825,733 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTACentessa Pharmaceuticals-0.08%-0.05%+0.03%+63.22%+217.66%IMVTImmunovant+2.09%+2.02%+16.44%+14.08%+108.63%SRRKScholar Rock+1.99%+6.39%+1.31%+7.52%+59.78%URGNUrogen Pharma+3.83%+17.87%+52.56%+53.09%+205.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTACentessa Pharmaceuticals$39.60+0.1%$34.74$10.95▼$40.26$5.91B1.132.28 million shs1.62 million shsIMVTImmunovant$28.96-1.0%$26.25$13.63▼$30.16$5.89B0.71.44 million shs1.22 million shsSRRKScholar Rock$51.28+2.2%$46.48$27.07▼$51.63$6.14B0.71.34 million shs2.21 million shsURGNUrogen Pharma$29.68-4.1%$21.37$3.42▼$32.37$1.45B1.58826,948 shs825,733 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTACentessa Pharmaceuticals-0.08%-0.05%+0.03%+63.22%+217.66%IMVTImmunovant+2.09%+2.02%+16.44%+14.08%+108.63%SRRKScholar Rock+1.99%+6.39%+1.31%+7.52%+59.78%URGNUrogen Pharma+3.83%+17.87%+52.56%+53.09%+205.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTACentessa Pharmaceuticals 2.21Hold$40.702.78% UpsideIMVTImmunovant 2.45Hold$32.4412.03% UpsideSRRKScholar Rock 3.17Buy$56.009.20% UpsideURGNUrogen Pharma 2.80Moderate Buy$36.6723.54% UpsideCurrent Analyst Ratings BreakdownLatest URGN, SRRK, IMVT, and CNTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026URGNUrogen Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $45.005/11/2026URGNUrogen Pharma LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$43.005/8/2026SRRKScholar Rock BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$53.00 ➝ $55.005/8/2026SRRKScholar Rock HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$58.00 ➝ $65.005/7/2026URGNUrogen Pharma OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$34.00 ➝ $40.004/24/2026URGNUrogen Pharma Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026SRRKScholar Rock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026SRRKScholar Rock Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$62.004/20/2026CNTACentessa Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026URGNUrogen Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CNTACentessa Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$35.00 ➝ $42.00(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTACentessa Pharmaceuticals$15M393.97N/AN/A$3.27 per share12.11IMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/ASRRKScholar RockN/AN/AN/AN/A$2.30 per shareN/AURGNUrogen Pharma$140.49M10.29N/AN/A($2.55) per share-11.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTACentessa Pharmaceuticals-$197.53M-$1.79N/AN/AN/AN/A-60.37%-44.17%N/AIMVTImmunovant-$413.84M-$2.69N/AN/AN/AN/A-63.17%-58.01%5/20/2026 (Estimated)SRRKScholar Rock-$377.94M-$3.59N/AN/AN/AN/A-163.52%-96.67%N/AURGNUrogen Pharma-$153.49M-$2.75N/A21.20N/A-94.83%N/A-62.85%N/ALatest URGN, SRRK, IMVT, and CNTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q4 2026IMVTImmunovant-$0.60N/AN/AN/AN/AN/A5/7/2026Q1 2026SRRKScholar Rock-$0.82-$0.83-$0.01-$0.83$5.00 millionN/A5/7/2026Q1 2026URGNUrogen Pharma-$0.4824-$0.47+$0.0124-$0.47$44.83 million$50.96 million5/5/2026Q1 2026CNTACentessa Pharmaceuticals-$0.38-$0.52-$0.14-$0.52N/AN/A3/31/2026Q4 2025CNTACentessa Pharmaceuticals-$0.38-$0.48-$0.10-$0.48$0.77 millionN/A3/3/2026Q4 2025SRRKScholar Rock-$0.86-$0.76+$0.10-$0.76N/AN/A3/2/2026Q4 2025URGNUrogen Pharma-$0.66-$0.54+$0.12-$0.54$39.92 million$37.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNTACentessa PharmaceuticalsN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTACentessa Pharmaceuticals0.239.539.53IMVTImmunovantN/A15.7415.74SRRKScholar Rock0.718.646.95URGNUrogen PharmaN/A4.694.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTACentessa Pharmaceuticals82.01%IMVTImmunovant47.08%SRRKScholar Rock91.08%URGNUrogen Pharma91.29%Insider OwnershipCompanyInsider OwnershipCNTACentessa Pharmaceuticals4.09%IMVTImmunovant1.80%SRRKScholar Rock13.30%URGNUrogen Pharma4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTACentessa Pharmaceuticals200149.23 million143.13 millionOptionableIMVTImmunovant120203.53 million199.87 millionOptionableSRRKScholar Rock140119.83 million103.89 millionOptionableURGNUrogen Pharma20048.72 million46.43 millionOptionableURGN, SRRK, IMVT, and CNTA HeadlinesRecent News About These CompaniesUroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13 at 2:03 PM | seekingalpha.comZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION TrialMay 13 at 8:00 AM | globenewswire.comURGN Share News TodayMay 12 at 10:27 PM | uk.investing.comUrogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?May 11 at 10:56 AM | zacks.comUrogen Pharma (NASDAQ:URGN) Now Covered by Analysts at LADENBURG THALM/SH SHMay 11 at 10:00 AM | marketbeat.comAssessing UroGen Pharma (URGN) Valuation After Q1 2026 Earnings Beat And Zusduri Launch MomentumMay 8, 2026 | finance.yahoo.comUroGen Pharma Ltd. (NASDAQ:URGN) Q1 2026 Earnings Call TranscriptMay 8, 2026 | insidermonkey.comUrogen Pharma (NASDAQ:URGN) Sets New 1-Year High Following Analyst UpgradeMay 8, 2026 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Given New $40.00 Price Target at OppenheimerMay 8, 2026 | americanbankingnews.comUroGen Pharma Earnings Call Highlights ZUSDURI SurgeMay 7, 2026 | tipranks.comUroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027May 7, 2026 | seekingalpha.comUrogen Pharma (NASDAQ:URGN) Stock Price Expected to Rise, Oppenheimer Analyst SaysMay 7, 2026 | marketbeat.comUroGen Pharma to Present at Upcoming Investor ConferencesMay 7, 2026 | globenewswire.comUrogen Pharma Q1 Earnings Call HighlightsMay 7, 2026 | marketbeat.comUroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call TranscriptMay 6, 2026 | seekingalpha.comUrogen Pharma (NASDAQ:URGN) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPSMay 6, 2026 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Trading Up 14% on Better-Than-Expected EarningsMay 6, 2026 | marketbeat.comUrogen Pharma (URGN) Reports Q1 Loss, Beats Revenue EstimatesMay 6, 2026 | zacks.comUroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and HighlightsMay 6, 2026 | globenewswire.comUrogen Pharma (URGN) Projected to Post Quarterly Earnings on WednesdayMay 2, 2026 | marketbeat.comUroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026April 29, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeURGN, SRRK, IMVT, and CNTA Company DescriptionsCentessa Pharmaceuticals NASDAQ:CNTA$39.60 +0.02 (+0.05%) Closing price 04:00 PM EasternExtended Trading$39.60 -0.01 (-0.01%) As of 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Immunovant NASDAQ:IMVT$28.96 -0.29 (-0.99%) Closing price 04:00 PM EasternExtended Trading$28.96 0.00 (0.00%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Scholar Rock NASDAQ:SRRK$51.28 +1.11 (+2.21%) Closing price 04:00 PM EasternExtended Trading$51.31 +0.03 (+0.06%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Urogen Pharma NASDAQ:URGN$29.68 -1.26 (-4.07%) Closing price 04:00 PM EasternExtended Trading$29.64 -0.04 (-0.12%) As of 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
